Register for our free email digests:
Division of Endo International PLC
Latest From Cellectis SA
Kala follows July's first biopharma IPO from Ionis spinout Akcea into the stock market. Amicus, Arena and othera go high with major offerings, while Inovio and Regulus go low. Also, Galena, Neothetics provide updates on their hunts for "strategic alternatives."
French ortho medical imaging specialist EOS imaging has made two new senior leadership appointments. Mike Lobinsky joins in a newly created role as US President while Pierre Schwich has been hired as the company's new CFO.
The FDA panel landmark recommendation for Novartis' CTL019 should provide a fillip for the other players in the CAR-T field but the response from the investment community has been lukewarm compared with researchers and patients.
UCART123 is behind the initial wave of CAR-T drugs for cancer but could have a big advantage as an allogeneic, or off-the-shelf, option. A Phase I trial is now under way in patients with acute myeloid leukemia.
- Controlled Release
- Generic Drugs
- Drug Delivery
- Therapeutic Areas
- Par Pharmaceutical Cos. Inc.
- Par Pharmaceutical Holdings Inc.
- Qualitest Pharmaceuticals
- Pharmaceutical Resources Inc.
- North America
- Parent & Subsidiaries
- Endo International PLC
- Senior Management
- Paul V Campanelli, Pres.
- Contact Info
Phone: (845) 573-5500
One Ram Ridge Rd.
Chestnut Ridge, NY 10977
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.